From Nasdaq:

The Japan’s Ministry of Health, Labour and Welfare approved VYVDURA injection for subcutaneous use in adult patients with generalized myasthenia gravis, who do not respond to steroids or non-steroidal immunosuppressive therapies. VYVDURA is now approved in Japan for both intravenous and self-administered SC use, based on positive results from the Phase 3 ADAPT-SC study. Hermann Strenger, General Manager, argenx Japan, stated that the approval provides two formulations for gMG patients, including the option to self-inject at home.

Source: rttnews.com



Read more: Argenx: Japan’s Ministry Of Health Approves VYVDURA Injection For Subcutaneous Use